There is evidence that inflammation would have an impact on the prognosis of patients experiencing acute coronary syndromes. The phospholipase A2 inhibitor Varespladib has positive effects on lipid and inflammatory markers.
This double-blind, multicenter planned to randomize 5145 patients with acute coronary syndrome to Varespladib or placebo. The primary endpoint was a combination of cardiovascular mortality, myocardial infarction, stroke, and unstable angina requiring hospitalization. In a pre- specified interim analysis 212 events were observed so suspension of the study was recommended for possible damage. Varespladib was associated with an increased risk of myocardial infarction (3.4 % versus 2.2 %, HR 1.66; CI 95%: 1,16-2, 39 9; p = 0.005).
Conclusion:
In patients with recent acute coronary syndrome Varespladib did not reduce the events and actually increase the risk of myocardial infarction.
Stephen Nicholls
2013-11-18
Original title: Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome.
